title: Aminopeptidase activity of an antitumor antibiotic, C-1027.
abstract: An antitumor antibiotic C-1027, a complex protein consisting of an apoprotein and a non-covalently bound chromophore, showed some aminopeptidase activity, 1/15 (on the basis of activity per mg protein) that of porcine kidney enzyme [E.C. 3.4.11.2] by use of L-phenylalanyl 4-methyl-coumaryl-7-amide as the substrate. Neither the apoprotein alone nor the chromophore alone were active. Amastatin and bestatin but not leupeptin inhibited the activity. The enzyme activity of the holo-antibiotic, as opposed to that of the porcine kidney enzyme, was readily lost by UV irradiation, indicating that the intact structure of the chromophore was needed to maintain the native conformation of the holo-antibiotic. The cytotoxicity of the holo-antibiotic, but not that of the chromophore, to Ehrlich carcinoma cells in vitro was reduced to 1/5 by 1 microgram/ml of amastatin which alone had no effect on cell growth. The porcine aminopeptidase was not cytotoxic at all even at higher concentrations (higher enzyme activities/ml). Amastatin possibly occupied the catalytic domain of the holo-antibiotic, interfering with the binding of the holo-antibiotic with some cell-surface protein(s). Amastatin did not inhibit the holo-antibiotic to cleave isolated DNA.
authors.affiliation: Showa College of Pharmaceutical Sciences, Tokyo, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Sakata
authors.forename: K S
authors.initials: KS
authors.lastname: Tsuchiya
authors.forename: Y
authors.initials: Y
authors.lastname: Moriya
authors.forename: H
authors.initials: H
authors.lastname: Hayashi
authors.forename: M
authors.initials: M
authors.lastname: Hori
authors.forename: T
authors.initials: T
authors.lastname: Otani
authors.forename: M
authors.initials: M
authors.lastname: Nagai
authors.forename: T
authors.initials: T
authors.lastname: Aoyagi
mesh_terms: D000617:Aminoglycosides; D000626:Aminopeptidases / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000528:radiation effects; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000903:Antibiotics, Antineoplastic / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism* / Q000528:radiation effects; D001059:Apoproteins / Q000378:metabolism; D002286:Carcinoma, Ehrlich Tumor; D002470:Cell Survival / Q000187:drug effects; D004273:DNA, Neoplasm / Q000187:drug effects; D053281:Enediynes; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D007976:Leupeptins / Q000494:pharmacology; D008861:Microsomes / Q000201:enzymology; D009842:Oligopeptides / Q000494:pharmacology; D010455:Peptides; D011506:Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism / Q000528:radiation effects; D013379:Substrate Specificity; D013552:Swine; D014407:Tumor Cells, Cultured; D014466:Ultraviolet Rays
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D001059:Apoproteins; D004273:DNA, Neoplasm; D053281:Enediynes; D007976:Leupeptins; D009842:Oligopeptides; D010455:Peptides; D011506:Proteins; C058024:C 1027; C016977:amastatin; D000626:Aminopeptidases; D007930:Leucine; C012211:ubenimex; C032854:leupeptin